Edwards Lifesciences (NYSE:EW – Get Free Report) posted its quarterly earnings data on Wednesday. The medical research company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.06, FiscalAI reports. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.25%. The firm had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.68 billion. During the same quarter last year, the company posted $0.67 EPS. The company’s quarterly revenue was up 10.5% compared to the same quarter last year.
Here are the key takeaways from Edwards Lifesciences’ conference call:
- Third-quarter sales rose 11.2% to $1.72 billion, and adjusted EPS was $0.80. Edwards raised full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97–$3.05.
- TAVR sales increased 8.8%, prompting the company to raise its 2026 TAVR growth outlook to 9%–9.5%. Management cited encouraging procedure trends and expects future growth to come more from market expansion than share gains, which have recently plateaued.
- TMTT sales surged 45.6% to $207 million, and Edwards now expects full-year TMTT sales of $780 million–$790 million. Management said its PASCAL, EVOQUE, and SAPIEN M3 portfolio supports a goal of $2 billion in TMTT revenue by 2030.
- New clinical evidence and the updated U.S. TAVR coverage policy may broaden treatment access over time, including for asymptomatic patients; management also sees potential for a future moderate-aortic-stenosis indication. Executives cautioned that adoption and the impact of these catalysts are expected to build gradually.
Edwards Lifesciences Stock Up 1.3%
Shares of NYSE EW opened at $100.70 on Friday. The firm has a market capitalization of $57.99 billion, a PE ratio of 56.90, a price-to-earnings-growth ratio of 2.60 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1 year low of $74.66 and a 1 year high of $104.17. The firm’s 50-day moving average is $88.68 and its 200-day moving average is $85.69.
Trending Headlines about Edwards Lifesciences
Here are the key news stories impacting Edwards Lifesciences this week:
- Positive Sentiment: Edwards reported Q3 revenue of $1.72 billion, up 11.2% year over year, and adjusted EPS of $0.80, beating estimates of $1.68 billion and $0.74. Growth in structural heart therapies helped drive the results; TMTT sales rose 45.6% and TAVR sales 8.8%. The company raised its full-year outlook, including adjusted EPS guidance of $2.97–$3.05. Read More.
- Positive Sentiment: New PROGRESS Trial data found TAVR reduced combined death or heart-failure outcomes versus active surveillance in at-risk patients with moderate aortic stenosis, with fewer heart-failure hospitalizations and better quality-of-life measures. Positive data, alongside expanded Medicare reimbursement, could support earlier use and more procedures. Read More.
- Positive Sentiment: Analysts responded to the results by lifting price targets and, in some cases, upgrading ratings. JPMorgan raised its target to $120 from $105, UBS to $118 from $110, and several other firms also increased targets; Baird and Truist upgraded the stock. The cluster of revisions signals improved confidence in EW’s outlook. Read More.
- Negative Sentiment: Management expects greater competition in transcatheter aortic valve replacement (TAVR). Competitive pressure could weigh on future growth or margins, even as current sales and trial results are encouraging. Read More.
Insider Transactions at Edwards Lifesciences
In related news, VP Daniel Lippis sold 619 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,428,912.10. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,045 shares of company stock worth $451,596 in the last quarter. 0.31% of the stock is owned by company insiders.
Analyst Ratings Changes
Several analysts have recently commented on the stock. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, October 27th. Deutsche Bank Aktiengesellschaft set a $104.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday, October 27th. Evercore restated an “outperform” rating on shares of Edwards Lifesciences in a research report on Friday, October 23rd. Wells Fargo & Company reaffirmed an “overweight” rating and set a $113.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Thursday. Finally, Mizuho set a $120.00 price objective on Edwards Lifesciences in a research report on Thursday. Twenty-three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.88.
Get Our Latest Analysis on Edwards Lifesciences
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.
Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.
Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.
Read More
- Five stocks we like better than Edwards Lifesciences
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
